Liu Xiujie, Su Jing, Shi Yu, Guo Ying, Suheryani Imran, Zhao Shicong, Deng Yulin, Meng Weiwei, Chen Yan, Sun Lili, Dai Rongji
School of Life Science, Beijing Institute of Technology, Beijing, PR China.
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, PR China.
Drug Dev Res. 2017 Jun;78(3-4):155-163. doi: 10.1002/ddr.21388. Epub 2017 May 19.
Preclinical Research Baogan Yihao (BGYH) is a traditional Chinese herbal medicine for the treatment of chronic liver diseases. In this study, the effects of BGYH on dimethylnitrosamine (DMN)-induced liver fibrosis were investigated using a rat model. BGYH alleviate liver damage, as indicated by decreased levels of AST, ALT, γ-GT, and AKP. BGYH also prevented collagen deposition and reduced pathological tissue injury in liver tissue. In fibrosis, high levels of α-SMA and TGF-β in liver tissue were markedly attenuated by BGYH. The inhibitory effect of BGYH on HSC-T6 proliferation demonstrated that BGYH exhibited significant hepatoprotective and antifibrogenic effects on DMN-induced liver injury. These findings suggest that BGYH may have therapeutic potential in the prevention and therapy of liver fibrosis. Drug Dev Res 78 : 155-163, 2017. © 2017 Wiley Periodicals, Inc.
临床前研究 保肝益号（BGYH）是一种用于治疗慢性肝病的传统中药。在本研究中，使用大鼠模型研究了BGYH对二甲基亚硝胺（DMN）诱导的肝纤维化的影响。BGYH减轻了肝损伤，表现为AST、ALT、γ-GT和AKP水平降低。BGYH还可防止肝组织中的胶原沉积并减轻病理组织损伤。在肝纤维化过程中，BGYH可显著降低肝组织中高水平的α-SMA和TGF-β。BGYH对HSC-T6增殖的抑制作用表明，BGYH对DMN诱导的肝损伤具有显著的肝保护和抗纤维化作用。这些发现表明，BGYH在肝纤维化的预防和治疗中可能具有治疗潜力。《药物研发研究》78: 155 - 163, 2017。© 2017威利期刊公司。
